- Home
- KMDA vs FINS Comparison
KMDA vs FINS Comparison
Compare KMDA & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- FINS
- Stock Information
- Founded
- KMDA 1990
- FINS 2019
- Country
- KMDA Israel
- FINS United States
- Employees
- KMDA N/A
- FINS N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- FINS Finance/Investors Services
- Sector
- KMDA Health Care
- FINS Finance
- Exchange
- KMDA Nasdaq
- FINS Nasdaq
- Market Cap
- KMDA 398.5M
- FINS 447.8M
- IPO Year
- KMDA N/A
- FINS N/A
- Fundamental
- Price
- KMDA $6.95
- FINS $13.07
- Analyst Decision
- KMDA Strong Buy
- FINS
- Analyst Count
- KMDA 2
- FINS 0
- Target Price
- KMDA $13.00
- FINS N/A
- AVG Volume (30 Days)
- KMDA 77.7K
- FINS 78.0K
- Earning Date
- KMDA 11-12-2025
- FINS 01-01-0001
- Dividend Yield
- KMDA 2.88%
- FINS 9.97%
- EPS Growth
- KMDA 27.97
- FINS N/A
- EPS
- KMDA 0.32
- FINS N/A
- Revenue
- KMDA $169,517,000.00
- FINS N/A
- Revenue This Year
- KMDA $14.49
- FINS N/A
- Revenue Next Year
- KMDA $10.12
- FINS N/A
- P/E Ratio
- KMDA $21.01
- FINS N/A
- Revenue Growth
- KMDA 9.67
- FINS N/A
- 52 Week Low
- KMDA $5.43
- FINS $11.61
- 52 Week High
- KMDA $9.16
- FINS $12.57
- Technical
- Relative Strength Index (RSI)
- KMDA 52.44
- FINS 46.91
- Support Level
- KMDA $6.72
- FINS $12.98
- Resistance Level
- KMDA $7.11
- FINS $13.20
- Average True Range (ATR)
- KMDA 0.19
- FINS 0.13
- MACD
- KMDA 0.03
- FINS 0.00
- Stochastic Oscillator
- KMDA 60.68
- FINS 50.57
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.